Supplementary Data S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)

This publication has 65 references indexed in Scilit:

• The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials
  European Journal of Cancer, 2017
• Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy
  Molecular Diagnosis & Therapy, 2017
• Incorporation of FcRn‐mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients
  Biopharmaceutics & Drug Disposition, 2015
• Ovarian cancer treatment: The end of empiricism?
  Cancer, 2015
• Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
  Pharmaceutical Research, 2014
• Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration
  International Journal of Cancer, 2014
• Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome
  Pediatric Blood & Cancer, 2008
• Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
  Journal of Surgical Oncology, 2005
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 Report
  JAMA, 2003
• Frequent expression of the tumor antigen cak1 in squamous‐cell carcinomas
  International Journal of Cancer, 1992